![](https://investorshub.advfn.com/uicon/341783.png?cb=1583853296)
Wednesday, September 05, 2012 1:31:55 PM
August 27, 2012 13:32 ET
Continuous Manufacturing Improvements Yield Significant Margin Expansion; Reduction of Greater Than 33% in Cost of Goods Across Company's Product Range
NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwire - Aug 27, 2012) - Avita Medical Ltd. (ASX: AVH), (PINKSHEETS: AVMXF), (OTCQX: AVMXY), the regenerative medicine company, announced a brief summary of recent manufacturing improvements, a direct result of the combined efforts of R&D and Operations and implementation of the company's commitment to a Continuous Improvement Model.
Modifications and improvements in manufacturing have generated a reduction of greater than 33% in cost of goods of the company's products over the past 18 months. Recent manufacturing changes and product improvements will be yielding significant additional increases in margins in the near term. These include:
Respiratory Products - In July 2012 Avita Medical completed relocation of manufacture of its respiratory product line (Breath A Tech® and Funhaler®) to Guppy Plastics, located in Malaysia. Guppy is a high quality manufacturer of plastic products supporting such diverse customers as Flextronics, Raymarine, Continental, McDonalds and Kelloggs. Avita is benefiting meaningfully from Guppy's ability to leverage material procurement volumes to provide a full turnkey arrangement with Avita while reducing manufacturing costs by approximately 11%. The improved manufacturing margins will be recognized over the coming months as Avita commences shipment of the new, higher margin product.
Regenerative Products - Avita has worked closely with its manufacturer to implement a number of recent improvements to ReCell® Spray-On Skin® based on customer feedback, best manufacturing practises and component cost improvements. In addition, R&D work focused on both product and field of use has significantly enhanced the margins across all proposed applications of the proprietary ReCell intellectual property. These changes to the ReCell product have included:
Improved and more customer friendly packaging and ease of use through improved mechanics, software and labelling.
Revised and improved manufacturing process including a Turn Key purchasing agreement yielding significant saving in materials procurement.
Manufacturing of the proprietary ReCell Enzyme has been relocated to a specialist US-based manufacturer yielding significant advances in the manufacturing process and performance. Crucially, the new manufacturing process, while meeting all specification requirements, will provide improved availability and contributes to a significant decrease in the cost of goods.
"The significant improvements to Avita's products and manufacturing process have yielded important and quantifiable benefits in product quality, increased margins and reductions in operating costs," said Dr. William Dolphin, CEO of Avita Medical. "Moreover, the new manufacturing ensures ready availability of the ReCell Enzyme, a critical factor as demand for ReCell grows worldwide.
"The company is committed to our Continuous Improvement model with tight control of our Quality and Manufacturing Systems a prerequisite for efficient operations. We look forward to announcing additional improvements as we continue to reach our key milestones."
insert-text-here
Recent RCEL News
- AVITA Medical to Announce Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 07/11/2024 08:10:00 PM
- AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary • GlobeNewswire Inc. • 07/01/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 12:48:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:36:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:39:30 PM
- AVITA Medical Achieves Milestone with First Case Using RECELL GO • GlobeNewswire Inc. • 06/05/2024 08:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:34:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:28:05 PM
- AVITA Medical Announces FDA Approval of RECELL GO • GlobeNewswire Inc. • 05/30/2024 01:15:00 PM
- AVITA Medical to Host Investor Webinar Briefing • GlobeNewswire Inc. • 05/16/2024 10:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:02:24 PM
- AVITA Medical Reports First Quarter Financial Results • GlobeNewswire Inc. • 05/13/2024 08:01:00 PM
- AVITA Medical to Announce First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/15/2024 09:05:00 PM
- AVITA Medical Updates Expected First Quarter 2024 Revenue • GlobeNewswire Inc. • 04/10/2024 09:11:25 PM
- AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement • GlobeNewswire Inc. • 02/29/2024 09:02:00 PM
- AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/29/2024 02:00:00 PM
- AVITA Medical to Host Investor Webinar Briefing • GlobeNewswire Inc. • 02/23/2024 02:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:02:06 PM
- AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance • GlobeNewswire Inc. • 02/22/2024 09:01:00 PM
- AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/01/2024 09:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:12 PM
- AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific • GlobeNewswire Inc. • 01/10/2024 09:01:00 PM
- AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update • GlobeNewswire Inc. • 01/10/2024 02:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 10:51:10 PM
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM